Clinical Trials Browser

Neoplasm, Residual × blinatumomab × 90 days × Clear all

NCT04521231 2026-05-28

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Phase 1/2 Active not recruiting

Burkitt Lymphoma, Recurrence, Neoplasm, Residual